AI Automated Translation.

Font Size

Share

OncoNic Therapeutics turns to a loss in Q3… Impact of expanded R&D investment

OncoNic Therapeutics turns to a loss in Q3… Impact of expanded R&D investment

Revenue down 11.5% year-on-year to 17 billion won… Operating loss of 4.3 billion won
Cumulative revenue up 70% to 64.4 billion won… Maintains cumulative profit on the back of expanded Zaqubo prescriptions

OncoNic Therapeutics' operating profit for the third quarter of this year turned negative compared to the same period last year, driven by a decline in revenue and increased research and development (R&D) investment. However, on a cumulative basis through the third quarter, the company maintained revenue growth and an operating surplus, fueled by the expanded prescription of its self-developed new drug, "Zaqubo."

OncoNic Therapeutics disclosed on the 16th that its revenue for the third quarter of this year was 17 billion won, a decrease of 11.5% from 19.2 billion won in the same period last year. During the same period, the operating loss was 4.3 billion won, marking a shift into the red. The net loss for the current period was recorded at 7.7 billion won.

The decline in third-quarter revenue was influenced by reduced production volumes due to summer vacations and other factors. Additionally, increased R&D expenses resulting from research on new drug candidates and expanded clinical trials both domestically and internationally contributed to the shift into an operating deficit. The net loss for the current period included non-cash foreign currency translation losses arising from exchange rate fluctuations in dollar-denominated assets held as consideration for overseas technology transfer.

In fact, R&D expenses incurred in the third quarter were 10.1 billion won, approaching the approximately 10.5 billion won spent on R&D across the entire first half of the year. Consequently, cumulative R&D expenses for the first three quarters of this year reached 20.7 billion won, an increase of approximately 3.4 times compared to 6.1 billion won in the same period last year.

Cumulative performance maintained a growth trend. Revenue from January to September this year was 64.4 billion won, up 70.3% year-on-year. Cumulative operating profit was 3 billion won, and net income for the current period was 2.5 billion won, both recording surpluses.

The growth in cumulative revenue was supported by the expanded prescription of Zaqubo, a treatment for gastroesophageal reflux disease and the 37th domestically developed new drug. According to pharmaceutical market research firm Ubist, Zaqubo's out-of-hospital prescription amount in the third quarter was 28.75 billion won, an increase of 109.6% year-on-year. In October last month, the monthly prescription amount exceeded 10 billion won for the first time, reaching 10.27 billion won.

Overseas commercialization of Zaqubo is also underway. Following product approval in India, approval procedures are currently in progress in China and Mexico.

OncoNic Therapeutics is focusing its R&D investment on the development of anti-cancer new drugs and new pipelines (drug candidates). Clinical development of the next-generation anti-cancer drug "Nesuparib" is underway for four cancer types: pancreatic cancer, endometrial cancer, ovarian cancer, and gastric cancer. The company is also advancing pre-submission consultations with the Food and Drug Administration (FDA) to enter U.S. clinical trials and preparing for the production of drugs for global clinical use.

Research results on "OCN-501," a candidate drug for muscle metabolism-related diseases, were selected as a latest research abstract at the American Society for Metabolic Syndrome conference and chosen for an oral presentation. The study focused on suppressing muscle loss that occurs during weight reduction when used in combination with glucagon-like peptide-1 (GLP-1) class obesity treatments.

An official from OncoNic Therapeutics stated, "The expansion of R&D investment is not merely a cost increase but an investment to secure future growth drivers, and it is yielding concrete results, such as the selection of new pipelines like OCN-501 for oral presentations at global academic conferences." The official added, "Based on a virtuous cycle growth model that reinvests profits secured through the commercialization of our first new drug into the development of subsequent new drugs, we will further expand global clinical development and overseas expansion of new pipelines next year."

"This article was translated using AI and may differ slightly from the original."